EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Agile Therapeutics's Enterprise Value is $7.87 Mil.
Agile Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was $-1.71 Mil. Therefore, Agile Therapeutics's EV-to-FCF for today is -4.61.
The historical rank and industry rank for Agile Therapeutics's EV-to-FCF or its related term are showing as below:
AGRX'
s EV-to-FCF Range Over the Past 10 Years
Min: -5.39 Med: -0.41 Max: 0.09
Current: -4.61
During the past 12 years, the highest EV-to-FCF of Agile Therapeutics was 0.09. The lowest was -5.39. And the median was -0.41.
AGRX's EV-to-FCF is not ranked
in the Drug Manufacturers industry.
Industry Median: 23.465
vs AGRX: -4.61
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
The historical data trend for Agile Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Agile Therapeutics's EV-to-FCF
For the Drug Manufacturers - Specialty & Generic subindustry, Agile Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agile Therapeutics's EV-to-FCF Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Agile Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Agile Therapeutics's EV-to-FCF falls into.
Agile Therapeutics's current Enterprise Value is $7.87 Mil.
Agile Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Agile Therapeutics's PE Ratio (TTM) for today is calculated as:
Agile Therapeutics's share price for today is $1.51.
Agile Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.130.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Agile Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Agile Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. The Company views its operations and manages its business in one operating and reporting segment, which is the business of commercializing its transdermal patch for use in contraception.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AGRX has been successfully added to your 